cagrisema cagrilintide semaglutide phase 3 results 2024 2025 obesity Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study Three new phase 3 REIMAGINE
Three new phase 3 REIMAGINE studies provide some of the strongest evidence yet for CagriSema (cagrilintide + semaglutide) in type 2 diabetes. REIMAGINE 1 Studied people with early type 2 diabetes CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure Nature Metabolism Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025 Novo Nordisk's next gen obesity drug CagriSema outperforms Wegovy in late stage diabetes trial : r mounjarouk Novo Nordisk's CagriSema outperforms Ozempic in Phase III trial Novo's Phase 3 CagriSema results disappoint analysts, sending stock tumbling MM+M Medical Marketing and Media
Pay in 4 interest-free payments of $6.59 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10




